Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri NCIMB 30242 and Improved Blood Lipid Profile

Research synthesisLow evidenceMixed effect size3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 studies, all reported beneficial effects of Lactobacillus reuteri NCIMB 30242 on blood lipid profiles, with effect sizes ranging from small to moderate. The most robust evidence comes from a single randomized controlled trial in hypercholesterolemic adults (n=127), which found small but significant reductions in LDL-C/HDL-C ratio (13.39%) and apoB-100/apoA-1 ratio (9.00%). The two remaining studies are reviews with minimal detail, and no consistent dose range or form was reported.

  • Studied populations: Hypercholesterolemic adults

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Only one study (an RCT) provides statistically significant findings with a defined effect size; the other two are reviews without original quantitative data or sample sizes. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).

Generated May 12, 2026
3 of 3 papers
Back to top